K
Klaus Krueger
Researcher at Praxis
Publications - 33
Citations - 882
Klaus Krueger is an academic researcher from Praxis. The author has contributed to research in topics: Rheumatoid arthritis & Internal medicine. The author has an hindex of 9, co-authored 28 publications receiving 776 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
Frank Buttgereit,Gisela Doering,Achim Schaeffler,Stephan Witte,Stanisław Sierakowski,Erika Gromnica-Ihle,Sławomir Jeka,Klaus Krueger,Jacek Szechiński,Rieke Alten +9 more
TL;DR: Modified-release prednisone is well tolerated, convenient to administer, and produces a clinically relevant reduction of morning stiffness of the joints in addition to all known therapeutic effects of immediate-releaseprednisone.
Journal ArticleDOI
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Hendrik Schulze-Koops,Klaus Krueger,Inka Vallbracht Vallbracht,Rebecca Hasseli,Alla Skapenko +4 more
TL;DR: Accumulating data suggest that baseline use of bDMARDs is not associated with worse COVID-19 outcome and that some caution may have to be applied when employing rituximab (RTX), a B-cell depleting b DMARD, in patients with immune-mediated disease.
Journal ArticleDOI
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis
Frank Buttgereit,Gisela Doering,Achim Schaeffler,Stephan Witte,Stanisław Sierakowski,E Gromnica-Ihle,Sławomir Jeka,Klaus Krueger,Jacek Szechiński,Rieke Alten +9 more
TL;DR: Prednisone chronotherapy with the MR tablet was safe and well tolerated and provided a sustained improvement which resulted in a better benefit to risk ratio of low-dose glucocorticoid treatment for at least 12 months.
Journal ArticleDOI
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Juergen Rech,Axel J. Hueber,Stephanie Finzel,Matthias Englbrecht,Judith Haschka,Bernhard Manger,Arnd Kleyer,Michaela Reiser,Jayme Fogagnolo Cobra,Camille P. Figueiredo,Hans-Peter Tony,Stefan Kleinert,Joerg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,Hanns-Martin Lorenz,H. Nuesslein,Rieke Alten,Joerg Henes,Klaus Krueger,Georg Schett +25 more
TL;DR: MBDA improved the prediction of relapses in patients with RA in stable remission undergoing DMARD tapering, and if combined with ACPA testing, allowed prediction of relapse in more than 80% of the patients.
Journal ArticleDOI
Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions
Stefan Kleinert,H-P Tony,Klaus Krueger,Detert J,Mielke F,Karin Rockwitz,R. Schwenke,Gerd-Rüdiger Burmester,Diel R,Martin Feuchtenberger,Christian Kneitz +10 more
TL;DR: In patient populations with low rates of TB incidence and BCG vaccination, the use of both TST and IGRA may maximise sensitivity in detecting LTBI but may also reduce specificity.